chronic heart failure
Conditions
Interventions
Test group :Qihong capsule
control group :Standard treatment of Western Medicine
Sponsors
Xinjiang Uygur Autonomous Region Institute of traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for chronic heart failure, and have a history of chronic heart failure for more than 3 months or clinical symptoms of heart failure for more than 3 months; 2. Heart failure patients with TCM syndrome differentiation of Qi deficiency and blood stasis; 3. Age 30-80 years old; 4. Left ventricular ejection fraction (LVEF) >= or = 450pg/ml; 5. NYHA cardiac function class II-III; 6. Those who received at least 2 weeks of standardized western medicine treatment and reached the optimal therapeutic dose; 7. Those who have not used traditional Chinese medicine for the treatment of heart failure within 2 weeks before enrollment; 8. Voluntarily participate in this clinical trial, understand and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who undergo coronary revascularization and cardiac resynchronization therapy within 12 weeks, or those who plan to undergo cardiac resynchronization therapy within 12 weeks; 2. Patients with severe primary diseases such as liver, kidney, hematopoietic system, tumor patients, severe neuroendocrine system diseases and mental illness; uncontrolled hypertension patients, systolic blood pressure >=180mmHg and/or diastolic blood pressure >=100mmHg; 3. Alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, and serum creatinine exceeded 2 times the upper limit of normal, and serum potassium was greater than 5.5 mmol/L; 4. Patients with acute myocarditis, hypertrophic cardiomyopathy with left ventricular outflow tract obstruction, restrictive cardiomyopathy, large aneurysm, arterial dissection, congenital heart disease, severe malignant arrhythmia, significant hemodynamic changes and unrepaired heart valve disease ; 5. Severe peripheral arterial disease, acute exacerbation of chronic obstructive pulmonary disease, pulmonary vascular disease such as primary pulmonary hypertension or pulmonary hypertension due to autoimmune diseases; 6. Pregnant or planning to become pregnant and lactating women; 7. Those with allergies, or those who are known to be allergic to therapeutic drugs; 8. Participate in other drug clinical investigators within 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| N-terminal natriuretic peptide precursor;6-minute walk test; | — |
Countries
China
Contacts
Public ContactHe Yi
Xinjiang Uygur Autonomous Region Institute of traditional Chinese Medicine
Outcome results
None listed